Investor's Champion
How to make your money go further

Patient capital needed here

23/02/2021 · Arcontech Group (ARC)  · Clinigen Group (CLIN)  · Tracsis (TRCS) 
AIM AIM Inheritance Tax potential Pharma and Biotech Technology UK

Companies covered here have been testing investors' patience with steady, if unspectacular, progress over recent years. One in particular is taking a very long time to make meaningful progress; could it be on the cusp of breaking out?

Tracsis: trading in-line and plenty of promiseTracsis (LON:TRCS), the provider of software, hardware, and data services for the rail, traffic data and wider transport industries, confirmed that trading for the first half of the year to 31 January 2021 was in line with expectations with high activity levels across large parts of its business. Group revenue is expected to be c.£22m (H1 2020: £26.4m), with growth in its Rail Technology & Services Division and lower sales in the Events and Traffic Data business units due to ongoing Covid restrictions. The overall impact of Covid on 1st half revenue is expected…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login